Bayer's Expert Mondays 2024
in collaboration with Inpart Connect

Knowledge Sharing for Innovators | Meet & Greet with Bayer Scouts & Scientific Finders

11 a.m. ET | 5 p.m. CET on select Mondays, February - December 2024

For more information on sessions, see below

Calling pre-seed and seed innovators and entrepreneurs in Oncology, Cell & Gene Therapy, Cardiovascular, Immunology, Radiology, and Digital Health! 

Do you have disruptive science but struggle to bring it to life in the entrepreneurial world? Bayer's passion is to enable and support standout healthcare innovation!

Take your innovation to new heights and join Bayer´s Expert Mondays 2024, a series of knowledge exchange sessions to supercharge your start-up’s growth. 

In 2023, Bayer's Expert Mondays brought together over 2,500 innovators across 13 sessions. Let's build on this success and continue Collaborating to Cure to bring breakthrough innovation to patients.

What you need to know

  • Each one-hour Bayer's Expert Monday includes a live Q&A with respective Bayer Experts.
  • You can stay for a Meet & Greet with Bayer Scouts & Scientific Finders. Please reserve 30 additional minutes in your schedule for the Meet & Greet after the Bayer Expert session.

  • These sessions are not intended for service providers, consultants, IT providers, etc. They are designed for drug developers and healthcare researchers seeking collaboration with big pharma and out-licensing opportunities later in their journey.

  • Session recordings are NOT distributed afterward. Live attendance is necessary to get the most out of the expert sessions and network with the Bayer Pharma team.

  • Each session has a maximum capacity of 500 participants.





white: All innovation

blue: C&G focus


Grow Your Innovation & Get it to Market 

26 Feb

Clinical Operations in 2050

Dr. Bernhard Glombitza

VP, Head of Clinical OPS EMEA & APAC

11 March

EU Legislative Impact on Emerging European Innovation

Dr. Daniel Steiners

SVP, General Manager Bayer Pharma Germany


Edouard Ohleyer

Access & Value Policy Lead, Global Pharma Public Affairs

22 April

Cell & Gene Market Access Planning Differences in EMEA & US 

Dr. Markus Frick 

Global Market Access Lead, Cell & Gene

13 May

Cell & Gene Regulatory Jungle in the EU & US

Dr. Isabelle Stoeckert



Dr. Gabriele Bräunlich

VP, RA EMEA, Head RA Strategy


Dr. Jana Napolitano

RA Strategy, New Modalities 

Prepare for Dealmaking

15 April

Global Deal Trends, incl. Cell & Gene deals

Yan Jiang, PhD

Sr. Dir. BD&L, BD Insights

24 June

How does Big Pharma Evaluate Partnering Offers? + Tips on Preparing Non-Conf. Pitch Decks

Sebastian Karrer

Head of BD&L EMEA CtC Hub EMEA


Tanja Bloser

Ecosystem Activation, CtC Hub EMEA




26 Aug

Co.Lab Global Incubators & Cell & Gene Translational Center Berlin

Dr. JP Kruse

Senior Director BD&L, Co.Lab Berlin


Dr. Daniel Forler

Senior Director BD&L 

30 Sept

Demystify Due Diligence with Big Pharma

Dr. Anja Moews &
Dr. Torsten Hertramp

Senior Directors BD&L, Due Diligence Center of Excellence

18 Nov

Overcome Challenges & Risks in Cell & Gene Manufacturing/CMC Development

Dr. Jens Vogel

SVP, Global Head of Biotech

2 Dec

Bayer´s Collaboration Models & Alliance Management

Dr. Hanna Eilken & Dr. Christoph Huwe

Senior Directors BD&L, Alliance Management

9 Dec 

Ingredients to Successful Partnerships: Big Pharma +  Biotech/Start-ups

Nicolas Becker & Jeremy Booth

Senior Directors BD&L, Alliance Management

Browse and meet with partners all year round

R&D professionals
Academic institutes
Biotech companies
Partnering conversations